Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (9)
  • Open Access

    ARTICLE

    Comparison of pegaspargase with concurrent radiation vs. P-GEMOX with sequential radiation in early-stage NK/T-cell lymphoma

    DEMEI FENG1,#, SHENRUI BAI1,#, GUANJUN CHEN1, BIBO FU1, CAILU SONG1, HAILIN TANG1, LIANG WANG2,*, HUA WANG1,*

    Oncology Research, Vol.33, No.4, pp. 965-974, 2025, DOI:10.32604/or.2024.057065 - 19 March 2025

    Abstract Objectives: The optimal treatment strategy for early-stage natural killer/T-cell lymphoma (NKTCL) remains unclear. This study aimed to evaluate and compare the clinical outcomes and adverse events (AEs) associated with two treatment regimens for early-stage NKTCL: pegaspargase with concurrent radiation therapy (P+CCRT) and pegaspargase, gemcitabine, and oxaliplatin (P-GEMOX) with sequential radiation therapy (SERT). Propensity score matching (PSM) was employed to ensure balanced comparison between these regimens. Methods: We assessed the efficacy of P+CCRT from a phase II trial and P-GEMOX combined with SERT using real-world data. PSM was conducted at a 1:1 ratio with a caliper… More >

  • Open Access

    ARTICLE

    Preventive effects of low-dose radiation and hypofractionated radiation plus anti-programmed cell death protein 1 on lung metastasis in breast cancer

    SHUANG CHEN1,2,#, XUEMEI DENG2,#, XINGTING HE2, KEWEI XIANG2, GUIHONG CHEN2, HONGRU YANG2,*

    Oncology Research, Vol.33, No.3, pp. 687-694, 2025, DOI:10.32604/or.2024.052133 - 28 February 2025

    Abstract Background: Previous experiments have demonstrated that hypofractionated radiation therapy (HFRT), low-dose radiation therapy (LDRT), and combined anti-programmed cell death protein 1 (αPD-1) can enhance the abscopal effect. Combined with the phenomenon of low prognosis in patients with breast cancer lung metastasis, our study establishes a mouse model and changes the irradiation regimen of LDRT to explore its preventive effect on breast cancer lung metastasis. Methods: The breast cancer subcutaneous graft tumor model was developed. Two-lung prophylactic LDRT was performed prior to the onset of lung metastases, in combination with HFRT (8 Gy, 3f), and αPD-1… More >

  • Open Access

    ARTICLE

    Is ypTNM staging a comparable predictor as pTNM staging for survival in non-metastatic rectal cancer after preoperative chemoradiation therapy?

    JEN-PIN CHUANG1,2,3, HSIANG-LIN TSAI4,5, WEI-CHIH SU4,6,7, PO-JUNG CHEN4,6, CHING-WEN HUANG4,5, TSUNG-KUN CHANG4,6,7, YEN-CHENG CHEN4,6, CHING-CHUN LI4,8, YUNG-SUNG YEH4,9,10, TZU-CHIEH YIN4,5,11, JAW-YUAN WANG4,5,6,12,13,*

    Oncology Research, Vol.32, No.11, pp. 1723-1732, 2024, DOI:10.32604/or.2024.052098 - 16 October 2024

    Abstract Background: The pTNM staging system is widely recognized as the most effective prognostic indicator for cancer. The latest update of this staging system introduced a new pathological staging system (ypTNM) for patients receiving neoadjuvant chemoradiotherapy (NACRT). However, whether the prognostic value of the ypTNM staging system for rectal cancer is similar to that of the pTNM staging system remains unclear. This study was conducted to compare the ypTNM and pTNM staging systems in terms of their prognostic value for patients with nonmetastatic rectal cancer undergoing proctectomy. Material and Methods: This study was conducted at a large teaching… More >

  • Open Access

    ARTICLE

    Combinational therapy with Myc decoy oligodeoxynucleotides encapsulated in nanocarrier and X-irradiation on breast cancer cells

    BEHROOZ JOHARI1,2,#,*, MILAD PARVINZAD LEILAN1,#, MAHMOUD GHARBAVI3, YOUSEF MORTAZAVI1, ALI SHARAFI2, HAMED REZAEEJAM4

    Oncology Research, Vol.32, No.2, pp. 309-323, 2024, DOI:10.32604/or.2023.043576 - 28 December 2023

    Abstract The Myc gene is the essential oncogene in triple-negative breast cancer (TNBC). This study investigates the synergistic effects of combining Myc decoy oligodeoxynucleotides-encapsulated niosomes-selenium hybrid nanocarriers with X-irradiation exposure on the MDA-MB-468 cell line. Decoy and scramble ODNs for Myc transcription factor were designed and synthesized based on promoter sequences of the Bcl2 gene. The nanocarriers were synthesized by loading Myc ODNs and selenium into chitosan (Chi-Se-DEC), which was then encapsulated in niosome-nanocarriers (NISM@Chi-Se-DEC). FT-IR, DLS, FESEM, and hemolysis tests were applied to confirm its characterization and physicochemical properties. Moreover, cellular uptake, cellular toxicity, apoptosis, cell More > Graphic Abstract

    Combinational therapy with Myc decoy oligodeoxynucleotides encapsulated in nanocarrier and X-irradiation on breast cancer cells

  • Open Access

    ARTICLE

    The effect of prior prostate cancer treatment on perioperative and pathological outcomes after cystectomy

    Kassem S. Faraj1, Weslyn D. Bunn2, Victoria S. Edmonds2, Mark D Tyson1

    Canadian Journal of Urology, Vol.29, No.5, pp. 11284-11290, 2022

    Abstract Introduction: A comprehensive analysis on outcomes in the perioperative and pathological setting in patients with a prior diagnosis of prostate cancer has not been performed. The objective of this study is to describe the effect of prior prostate cancer treatment on perioperative and pathological outcomes after cystectomy.
    Materials and methods: This was a retrospective review of all male patients who underwent cystectomy at our institution from 01/01/2007-01/01/2020. Patients who were previously diagnosed and treated for prostate cancer were identified and outcomes were assessed.
    Results: In 525 male patients, 132 (25.1%) had a diagnosis of prostate cancer prior to… More >

  • Open Access

    ARTICLE

    Stereotactic body radiation therapy with simultaneous integrated boost for prostate cancer: does MRI-targeted biopsy alter the boost field?

    Andrew M. Fang1, Zachary R. Burns1, Alexander P. Nocera1, Rex A. Cardan2, Jeffrey W. Nix1,3, Kristin K. Porter4,*, Andrew M. McDonald2,3,*, Soroush Rais-Bahrami1,3,4

    Canadian Journal of Urology, Vol.28, No.5, pp. 10817-10823, 2021

    Abstract Introduction: We aim to investigate if the addition of MRI-US fusion biopsy (FB) can aid in radiation planning and alter the boost field in cases of stereotactic body radiation therapy (SBRT) for prostate cancer with a simultaneous integrated boost (SIB) to a magnetic resonance imaging (MRI)-defined intraprostatic lesion.
    Materials and methods: Patients undergoing SBRT with SIB for biopsy-proven prostatic adenocarcinoma and a pre-radiation MRI were retrospectively reviewed. 36.25 Gy in 5 fractions was delivered to the entire prostate along with SIB of 40 Gy to an MRI-defined intraprostatic lesion. Demographic, radiation planning details, and post-procedural outcomes were… More >

  • Open Access

    ARTICLE

    Endostar, an Antiangiogenesis Inhibitor, Combined With Chemoradiotherapy for Locally Advanced Cervical Cancer

    Heming Lu*†1, Yuying Wu‡1, Xu Liu, Huixian Huang, Hailan Jiang, Chaohua Zhu, Yuping Man§, Zhaohong Chen, Xianfeng Long, Qiang Pang, Luxing Peng, Xianglong Li, Junzhao Gu, Shan Deng, Ligang Xing*

    Oncology Research, Vol.28, No.9, pp. 929-944, 2020, DOI:10.3727/096504021X16318716607908

    Abstract This phase II randomized clinical trial aimed to assess the efficacy and toxicity of Endostar, an antiangiogenesis inhibitor, combined with concurrent chemoradiotherapy (CCRT) for locally advanced cervical cancer (LACC). Patients with LACC were randomly assigned to either CCRT plus Endostar (CCRT+E arm) or CCRT alone (CCRT arm). All patients received pelvic intensity-modulated radiation therapy (IMRT) and brachytherapy. Weekly cisplatin was administered concurrently with IMRT. Patients in the CCRT+E arm also received concurrent Endostar every 3 weeks for two cycles. The primary endpoint was progression-free survival (PFS) and acute toxicities. The exploratory endpoint was the impact… More >

  • Open Access

    RESIDENT’S CORNER

    Long term control and preservation of renal function after multiple courses of stereotactic body radiation therapy for renal cell carcinoma

    Abhinav V. Reddy1,2, Matthew N. Mills1,3, Stanley L. Liauw4, Sujith Baliga5, Charles R. Kersh6

    Canadian Journal of Urology, Vol.26, No.2, pp. 9743-9745, 2019

    Abstract Renal cell carcinoma (RCC) is usually treated with surgery, with or without systemic therapy. For select patients, stereotactic body radiation therapy (SBRT) may be a suitable alternative. Although many reports exist on the successful use of SBRT, very few have described long term outcomes with regard to disease progression and renal function. We report a rare case of a single patient with primary, metastatic, and locally recurrent renal cell carcinoma who was successfully treated with SBRT. The patient has been disease-free for 8 years since treatment, with stable renal function even after two courses of More >

  • Open Access

    ARTICLE

    A Randomized Controlled Open-Label Pilot Study of Simvastatin Addition to Whole-Brain Radiation Therapy in Patients With Brain Metastases

    Manal El-Hamamsy*, Hesham Elwakil, Amr S. Saad, May A. Shawki*

    Oncology Research, Vol.24, No.6, pp. 521-528, 2016, DOI:10.3727/096504016X14719078133528

    Abstract Statins have been reported to have a potential radiosensitizing effect that has not been evaluated in clinical trials. The aim of this study was to evaluate the efficacy and safety of simvastatin in addition to whole-brain radiation therapy (WBRT) in patients with brain metastases (BM). A prospective randomized, controlled, open-label pilot study was conducted on 50 Egyptian patients with BM who were randomly assigned to receive 30-Gy WBRT (control group: 25 patients) or 30 Gy WBRT+ simvastatin 80 mg/day for the WBRT period (simvastatin group: 25 patients). The primary outcome was radiological response at 4… More >

Displaying 1-10 on page 1 of 9. Per Page